CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortez...

Descripción completa

Detalles Bibliográficos
Autores principales: Seckinger, Anja, Hillengass, Jens, Emde, Martina, Beck, Susanne, Kimmich, Christoph, Dittrich, Tobias, Hundemer, Michael, Jauch, Anna, Hegenbart, Ute, Raab, Marc-Steffen, Ho, Anthony D., Schönland, Stefan, Hose, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062598/
https://www.ncbi.nlm.nih.gov/pubmed/30079070
http://dx.doi.org/10.3389/fimmu.2018.01676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062598/
https://www.ncbi.nlm.nih.gov/pubmed/30079070
http://dx.doi.org/10.3389/fimmu.2018.01676

Ejemplares similares